Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (PsAer-IgY)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Mukoviszidose Institut gGmbH
Sponsor:
Information provided by (Responsible Party):
Mukoviszidose Institut gGmbH
ClinicalTrials.gov Identifier:
NCT01455675
First received: October 18, 2011
Last updated: February 20, 2014
Last verified: January 2014

October 18, 2011
February 20, 2014
October 2011
October 2016   (final data collection date for primary outcome measure)
Time from start of treatment (=Day 0) to the first recurrence of PA (Pseudomonas aeruginosa) in the sputum or throat cough swab or endolaryngeal suction [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01455675 on ClinicalTrials.gov Archive Site
  • • Change in FEV 1.0 from day 0 to each visit [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Change in BMI from day 0 to each visit [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Number of exacerbations [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Number of days of illness in hospital and at home, i.e. out of school or work [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Control of use of antibiotics, especially anti-pseudomonas antibiotics -measured as days with antibiotic treatment [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Change in values of serologic tests for PA precipitins from day 0 to each visit (if applicable) [ Time Frame: max. 24 months ] [ Designated as safety issue: No ]
  • • Good tolerability and comparable number and quality of adverse events like placebo group [ Time Frame: max. 24 months ] [ Designated as safety issue: Yes ]
  • • Sputum or throat cough swab or endolaryngeal suction cultures for bacteria and fungi [ Time Frame: max. 24 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients

The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa after successfully treated acute or intermittent infection.

This is a double -blind, placebo controlled study in which the investigational drug and the reference placebo group are gargled and swallowed. 70 ml IgY/ placebo solution is gargled every night for two minutes (for maximal 24 months) The design will include the recruitment of 144 patients randomized in two groups (72 per treatment group) In order to compensate for dropouts (i.e. patients dropping out prior to 24 months without having an event) the total sample size is planned to be approximately 180 (i.e. ~20 % dropout rate).

During the two years of treatment, subjects will be examined at the clinic every 3 months regarding safety and efficacy of the medication.

For more information please see www.impactt.eu The IMPACTT Project is funded by EU within the Framework 7 Program. PsAer-IgY Studie is part of IMPACTT Project (Workpackage 2).

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Cystic Fibrosis
  • Drug: IgY
    Avian polyclonal anti-pseudomonas antibodies (IgY)
  • Drug: Placebo
    Placebo, 70 ml gargling solution, once daily
  • Experimental: IgY, gargling solution
    Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
    Intervention: Drug: IgY
  • Placebo Comparator: Placebo, gargling solution
    70 ml gargling solution without antibodies, once daily
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
180
Not Provided
October 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • CF patients diagnosed according to specific clinical features and either a positive sweat chloride in double proofs or presence of disease-associated CFTR mutations in both alleles
  • Males and females 5 years of age and above (being able to gargle)
  • CF patients having a FEV1 value between 50% and 130% of predicted value (according to Knudson formula)
  • CF patients who have had one to several sputum or throat cough swabs or endolaryngeal suction cultures positive for PA within the last three years and for whom PA has been successfully eradicated.
  • Sputum / throat cough swab/ endolaryngeal suction culture negative for PA and other gram-negative bacteria on study entry.
  • Patients and/ or their legal representative who are willing and able to give informed consent/ assent to participate in the study after thorough information
  • Subjects of child bearing potential and who are sexually active must meet the contraception requirements (i.e. oral or injectable contraceptives, intrauterine devices, double-barrier method, contraceptive patch, male partner sterilization or condoms).

Exclusion Criteria:

  • Microbiologic or serologic evidence of chronic infection with PA. Definition of chronic PA infection: Three cultures (sputum or throat cough swabs or endolaryngeal suction) have been positive for PA for 6 consecutive months (at least 3 cultures have to be taken) or more, .
  • Patients, who have positive sputum culture or throat cough swab or endolaryngeal suction culture for gram-negative bacteria, such as PA, S. maltophilia, B. cepacia, A. xylosoxidans (eradication before entry in study is possible), Patients, who have positive sputum culture or throat cough swab or endolaryngeal suction culture for atypical Mycobacteria and / or Aspergillus fumigates, associated with clinical symptoms that may necessitate specific treatment.
  • History of allergy/hypersensitivity to hens' egg proteins (including medication allergy) that is deemed relevant to the trial by the investigator. "Relevance" in this context refers to any increased risk of hypersensitivity reaction to trial medication.
  • Patient with a known relevant substance abuse, including alcohol or drug abuse.
  • Start of a new concomitant or chronic medication for CF within 4 weeks before inclusion.
  • Clinically relevant diseases or medical conditions other than CF or CF-related conditions that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data. This includes, but is not limited to, significant hematological, hepatic, renal, cardiovascular, and neurological diseases (diabetic patients may participate if their disease is under good control prior to inclusion).
  • Participation in another study with an investigational drug within one month or 6 half-lives (whichever is greater) preceding the inclusion.
  • The patient is an employee of the investigator or the institution with direct involvement in the trial or other trials under the direction of the investigator or their members.
  • Patients who are pregnant cannot be included into the study. This will be tested at inclusion visit with a urine pregnancy test (in female patients older than 10 years with secondary sexual characteristics)
Both
5 Years and older
No
Contact: Jutta Bend, Dr. +49 (0)228 ext 9878047 jbend@muko.info
Belgium,   Germany,   Ireland,   Italy,   Sweden
 
NCT01455675
PsAer-IgY
Yes
Mukoviszidose Institut gGmbH
Mukoviszidose Institut gGmbH
Not Provided
Principal Investigator: Antje Schuster, Prof. Dr. Universitätsklinikum Düsseldorf
Mukoviszidose Institut gGmbH
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP